Skip to content

Efficacy and Acceptability of the Luna EMG Rehabilitation Robot on Motor Recovery of the Upper Limb in the Chronic Phase of Stroke

Efficacy and Acceptability of the Luna EMG Rehabilitation Robot on Motor Recovery of the Upper Limb in the Chronic Phase of Stroke, Experimental Study in Single Cases.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05902910
Acronym
LUNASTROKE
Enrollment
5
Registered
2023-06-15
Start date
2023-06-12
Completion date
2026-06-12
Last updated
2026-06-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke

Keywords

Robot, Joint

Brief summary

Recent work on large cohorts of chronic stroke (\>6 months post-stroke) have shown that intensive training of the upper limb in the chronic stroke patients can lead to substantial motor and functional gains that are maintained at 6 months post intervention. A very prolonged (12 weeks) and very intensive (5 hours daily) training applied to chronic patients after stroke brings a substantial gain both motor and functional which is maintained at 3 months post intervention. Robotic rehabilitation have been shown to be as effective as any other treatment used in rehabilitation. But the methods of implementation remain widely debated. At that time, most robotic therapies have tried to reproduce functional movement mainly pointing objects. We want to demonstrate that analytic movements of the elbow and the shoulder performed with the Luna-EMG robot can replace part of usual physiotherapy treatment with at least the same effectiveness on the recovery of fluid movements of the upper limb after a stroke.

Detailed description

This is a pilot study following a single case experimental design with multiple baselines across subjects (MBD). People included in the protocol will benefit from 2 hours of daily treatment during 6 to 7.5 weeks. The first 2 weeks will be dedicated to baseline measurement of their upper limb (UL) status with daily treatment for balance and gait control without any treatment of the upper limb. The rest of the time will be dedicated to upper limb treatment exclusively. It will be divided into 2 UL training periods, one of them including a 30mn treatment with the luna EMG robot. The duration of second period will be randomly defined between 2 to 3.5 weeks and the last period will last 2 weeks. The treatment during the first UL treatment period will be randomly allocated to Luna EMG treatment or not. The next period will thus follow the inverse scheme (without if the first contains Luna EMG treatment). The fluidity will be assessed through pointing movements assessed every two days. Evaluation of motor deficiency (Fugl Meyer) and functional status (ARAT score) of the UL will be weekly assessed after the inclusion visit. 3D motion analysis of the UL will also be weekly performed. All patients will benefit from a regular follow-up and from an organized care protocol. The sessions will be intensive, all subjects will be able to benefit from the new treatment (LUNA EMG). We can expect a direct individual benefit from the proposed intensive treatment, at least for precision of UL movements.

Interventions

DEVICELUNA-EMG Robot

During phase B, patients will benefit from functional rehabilitation of their upper limbs and from 30mn of training assisted by the LUMA-EMG robot.

Sponsors

University Hospital, Brest
Lead SponsorOTHER
EGZOTech
CollaboratorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Outcomes Assessor)

Masking description

Assessors will not know what phase the patient is in at the time of assessment or what experimental design the patient was randomized to.

Intervention model description

The multiple-baseline SCED design is a prospective design that allows the intensive study of a few individuals to measure their baseline and condition related to a therapeutic intervention. Each subject is his own control with repeated measurements of the primary endpoint. Randomization in the MBD formats of SCED studies relates to the duration of the phases. The experimental plan includes 3 rehabilitation phases: A (Baseline), B (1.5hours a day 5/7 of conventional rehabilitation and 30mn of training with the Luna robot 5/7) and C (2 hours a day 5/7 of conventional rehabilitation). The duration of phase A is fixed (2 weeks). As the effect of the treatment on the upper limb is unknown in its latency, the duration of the second phase of the study will be randomized (2 to 3.5 weeks). Finally, the duration of the third phase is fixed (2 weeks)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age \>= 18 years * Hemiparesis after a first stroke with more than 1 year time interval * Functional upper limb: ability to do a pointing task at 90% of the hand-acromion distance (free trunk). * Spastic hypertonia of the elbow flexors 0-2/4 on the Modified Ashworth scale * Patient affiliated with social security * Patient having signed a consent to participate in the research

Exclusion criteria

* Inability to sign written consent * Flexed elbow \> 30° during passive mobilization of the upper limb * EVA\>3 in the upper limb at rest or during mobilization * Complete loss of upper limb proprioception * Neuro-orthopedic surgery of the upper limb for spasticity: neurotomy, tenotomy, transfer * Pregnant or breastfeeding woman

Design outcomes

Primary

MeasureTime frameDescription
Fluidity of the upper limbup to 7.5weeksRepeated evaluation of hand movement by the SPARC index during five pointing tasks at 90% of the length of the upper limb at clavicle height, at comfortable speed.

Secondary

MeasureTime frameDescription
Pain assessmentup to 7.5weeksUse of Visual Analog Scale (VAS) to evaluate the painful (between 0: no pain to 10: intolerable pain)
Motricity assessmentup to 7.5weeksUse of the Fugl-Meyer index (between 0: no motricity to 66: total member motricity)
Function assessmentup to 7.5weeksARAT (Action Research Arm Test) measurement to assess specific changes in limb function (from 0 to 57, a low score indicating that the movements cannot be performed, and a high score indicating normal performance)
Duration of movementup to 7.5weeksKinematic parameter measured 3 times per week
Straightness of movementup to 7.5weeksKinematic parameter measured 3 times per week : the trajectory of the hand during pointing movement at a distance normalised by the length of the upper limb will be assessed in motion capture (12 VICONR cameras). The smoothness of the trajectory will be measured by the SPARC (spectral arc length measure) during forward and backward movement.
Average speed of movementup to 7.5weeksKinematic parameter measured 3 times per week : the trajectory of the hand during pointing movement at a distance normalised by the length of the upper limb will be assessed in motion capture (12 VICONR cameras). The spatiotemporal parameters (time, distance, average speed) will be measured between the starting position (in front of the trunc) and the final pointed object during forward and backward movement.
Acceptability of the use of the robotup to 7.5weeksScore between 0 to 100 (a low score indicate that the robot is not well accepted, and a high score indicate a well acceptability)
Satisfaction of the use of the robotup to 7.5weeksScore between 0 to 100 (0: not satisfied, 100: very satisfied)
Spasticityup to 7.5weeksAshworth scale measured 3 times a week and Nottingham scale measured 1 time at inclusion)

Countries

France

Contacts

CONTACTOlivier Remy-Neris, PU-PH
olivier.remyneris@chu-brest.fr+33 2 98 22 31 52
CONTACTGwenaël Cornec, MD
gwenael.cornec@chu-brest.fr
PRINCIPAL_INVESTIGATOROlivier Remy-Neris, PU-PH

CHRU BREST

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 11, 2026